The safety of indocyanine green in patients with advanced chronic kidney disease or kidney transplantation: a scoping review
Authors:
- Mo W. Bsc KruiswijkMKMo W. Bsc Kruiswijk
- Ha Lan Bsc Nguyen DinhHDHa Lan Bsc Nguyen Dinh
- Floris P. Bsc TangeFTFloris P. Bsc Tange
- Stefan KoningSKStefan Koning
- Pim van Den HovenPHPim van Den Hoven
- Roderick C. Bsc PeulRPRoderick C. Bsc Peul
- Joris I. RotmansJRJoris I. Rotmans
- Volkert A.L. HuurmanVHVolkert A.L. Huurman
- Ian P.J. AlwaynIAIan P.J. Alwayn
- Jaap F. HammingJHJaap F. Hamming
- Alexander L. VahrmeijerAVAlexander L. Vahrmeijer
- Joost R. van der VorstJoost R. van der Vorst
Open Access
- 18 November 2024
- journal article
- review article
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (3) , 1351-1359
Abstract
Near-infrared fluorescence imaging with indocyanine green (ICG) is increasingly being used in the field of image-guided surgery. Although ICG is considered non-nephrotoxic in current literature, caution is advised for the use of ICG in patients with advanced chronic kidney disease (CKD), including kidney transplant recipients. Therefore, a scoping review was performed to assess the safety of ICG in patients with advanced CKD or a renal allograft. This scoping review was guided by the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-analyses Extension for Scoping Reviews). Web of Science, PubMed, and Embase were searched for articles and abstracts in which ICG was administered in patients with CKD or a renal allograft. The extracted data included the incidence of adverse events, kidney function after injection of ICG, preservation of transplant function, and type of other possible complications. The initial search resulted in 635 records of which 19 studies were found eligible for the review. ICG was used for multiple purposes but never specifically as an objective to investigate possible nephrotoxicity. No adverse events were reported in the transplant group (n=250) or the CKD group (n=74). Despite ICG-injection, preservation of transplant function after transplantation surgery was 94% in 198 patients, and no increase in possible ICG-related other complications was reported. This scoping review found no evidence that ICG increases the risk of adverse events in patients with CKD, including kidney transplant recipients. Therefore, the administration of ICG should not be withheld from these patients.Keywords
This publication has 54 references indexed in Scilit:
- Exploring the Link Between Hepatic Perfusion and Endotoxemia in HemodialysisKidney International Reports, 2021
- Current Role and Indications for the Use of Indocyanine Green in Robot-assisted Urologic SurgeryEuropean Urology Focus, 2018
- Indocyanine Green Angiography to Prognosticate Healing of Foot Ulcer in Critical Limb Ischemia: A Novel TechniqueAnnals of Vascular Surgery, 2018
- Hypersensitivity reactions in patients receiving hemodialysisAnnals of Allergy, Asthma & Immunology, 2017
- Measurement of Cardiac Output and Blood Volume During Hemodialysis with Fluorescent Dye Dilution TechniqueAnnals of Biomedical Engineering, 2016
- Contrast-Induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variablesThe American Journal of Cardiology, 2005
- High in vitro spontaneous histamine release in long-term hemodialyzed patientsJournal of Allergy and Clinical Immunology, 1990
- Adverse reactions to indocyanine green: A case report and a review of the literatureCatheterization and Cardiovascular Diagnosis, 1989
- Pharmacokinetics and Hepatic Extraction Ratio of Pindolol in Hypertensive Patients with Normal and Impaired Renal FunctionThe Journal of Clinical Pharmacology, 1977
- Adverse reactions associated with the administration of a tricarbocyanine dye (Cardio-Green) to uremic patientsJournal of Allergy and Clinical Immunology, 1971